Hep B Pol Antibody (2C8): sc-81590

Hep B Pol Antibody (2C8) is a mouse monoclonal IgG1 kappa light chain antibody that detects the Hep B Pol protein of Hepatitis B origin by western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Hep B Pol (2C8) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Hep B Pol (Hepatitis B polymerase) protein plays a crucial role in the viral life cycle as Hep B Pol protein is responsible for the reverse transcription of the Hepatitis B virus RNA genome into double-stranded DNA, which is essential for viral capsid formation. This enzyme not only copies both DNA and RNA templates but also has the unique ability to excise RNA strands from DNA-RNA heteroduplexes, thereby facilitating efficient virus replication. Hep B Pol protein is encapsidated within a continuous core shell along with pregenomic RNA, where Hep B Pol protein initiates reverse transcription by binding to the epsilon loop of the pgRNA. The process is primed by covalent attachment of Hep B Pol protein to a negative-sense DNA strand, which extends to form a complete strand, followed by positive-sense strand synthesis. HSP 70 and HSP 40 host cell chaperones mediate Hep B Pol protein activation, while reverse transcriptase inhibitors can block Hep B Pol protein activity. Notably, Hep B Pol protein contains a terminal protein domain specific to Hepadnaviruses, highlighting Hep B Pol protein′s importance in viral replication and significance as a therapeutic target.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Hep B Pol Antibody (2C8) References:

1. Profound suppression of hepatitis B virus replication with lamivudine.  |  Lai, CL. and Yuen, MF. 2000. J Med Virol. 61: 367-73. PMID: 10861648
2. Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.  |  Hadziyannis, SJ. and Papatheodoridis, GV. 2004. Expert Rev Anti Infect Ther. 2: 475-83. PMID: 15482214
3. Hepatitis B virus replication.  |  Beck, J. and Nassal, M. 2007. World J Gastroenterol. 13: 48-64. PMID: 17206754
4. Inhibition of hepatitis B virus polymerase by entecavir.  |  Langley, DR., et al. 2007. J Virol. 81: 3992-4001. PMID: 17267485
5. Occult hepatitis B virus in liver tissue of individuals without hepatic disease.  |  Raimondo, G., et al. 2008. J Hepatol. 48: 743-6. PMID: 18314221
6. COOH-terminal deletion of HBx gene is a frequent event in HBV-associated hepatocellular carcinoma.  |  Liu, XH., et al. 2008. World J Gastroenterol. 14: 1346-52. PMID: 18322946
7. Monotherapy versus combination therapy for the treatment of chronic hepatitis B.  |  Carey, I. and Harrison, PM. 2009. Expert Opin Investig Drugs. 18: 1655-66. PMID: 19852566
8. Hepatitis B virus promotes autophagic degradation but not replication in autophagosome.  |  Yang, H., et al. 2015. Biosci Trends. 9: 111-6. PMID: 25971696
9. Main properties of duck hepatitis B virus DNA polymerase: comparison with the human and woodchuck hepatitis B virus DNA polymerases.  |  Fourel, I., et al. 1987. Antiviral Res. 8: 189-99. PMID: 3446017
10. Advancing beyond reverse transcriptase inhibitors: The new era of hepatitis B polymerase inhibitors.  |  Ranga, A., et al. 2023. Eur J Med Chem. 257: 115455. PMID: 37216809
11. Exploring the tolerable region for HiBiT tag insertion in the hepatitis B virus genome.  |  Murayama, A., et al. 2024. mSphere. 9: e0051824. PMID: 39345122
12. Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen.  |  Valenzuela, P., et al. 1979. Nature. 280: 815-9. PMID: 471053

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Hep B Pol Antibody (2C8) has 9 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Hep B Pol Antibody (2C8) Specifications

Alternate Product Name: Hepatitis B DNA polymerase

Product Clone Name: 2C8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: Hep B Pol

Epitope Species: Hepatitis B virus

Product Reactivity/Detection: amino acids 8-20 corresponding to the terminal protein (TP) region of Hepatitis B polymerase

Species Reactivity/Detection: Hepatitis B

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: Hepatitis B

Applications: WB, IP, IF

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 9 citations in various scientific publications

Available Conjugates/Forms for Hep B Pol Antibody (2C8): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin